Verastem, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated June 19, 2019, details a significant leadership transition at Verastem, Inc. (VSTM), a biopharmaceutical company incorporated in Delaware. The report covers events occurring between June 19, 2019, and June 25, 2019, specifically the resignation of the former CEO and the appointment of a new President and Chief Operating Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and separation terms.
- New Executive Compensation: Dan Paterson's annual base salary increased to $460,000 with a target annual bonus of 50% of base salary.
- Equity Grant: Mr. Paterson received an option to purchase 250,000 shares at an exercise price of $1.81 per share.
- Separation Costs: Robert Forrester is entitled to 13 months of base salary and COBRA premium payments.
Material Changes
The primary material change is the departure of Robert Forrester as President, Chief Executive Officer, and Board member, effective June 21, 2019. Concurrently, Dan Paterson was appointed President and Chief Operating Officer, serving as the principal executive officer. The Board of Directors reduced the number of authorized directors from eight to seven following Mr. Forrester's resignation.
Outlook, Risks, and Contingencies
Management Commentary: The filing outlines the terms of the Separation Agreement and Consulting Agreement with Mr. Forrester, ensuring a transition period where he serves in an advisory capacity until July 21, 2022.
Compensation Contingencies:
- Mr. Paterson: Stock options vest 50% on the one-year anniversary of the grant date, with the remainder vesting quarterly thereafter, contingent on continued service.
- Mr. Forrester: Time-based unvested options vesting within 25 months of separation automatically become fully vested. Performance-based options remain eligible to vest based on metrics. Vested options remain exercisable until July 21, 2022.
Key Facts for Investor Verification
- Confirm the exact vesting schedule and exercise terms for the 250,000 options granted to Dan Paterson.
- Verify the total cash severance obligation for Robert Forrester (13 months of salary) and the impact on near-term cash flow.
- Review the specific performance metrics attached to Mr. Forrester's remaining performance-based stock options.
- Check the updated Board composition following the reduction from eight to seven authorized directors.